No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Sirtex Group agreement to enable collaboration on research and development of pharmaceutical products. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.
www.grandpharm.comNo one on the platform currently holds 0512.HK.
No tracked institution reports a position in 0512.HK as of their last filing.
No one on the platform has traded 0512.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.2% | 10.0% | 10.1% | — | — | — |
| Rev. Growth % | 5.5% | 14.1% | ||||
| Profit Margin % | 10.1% | 19.8% | 17.3% | |||
| Free Cash Flow Margin % | 6.3% | 11.1% | 12.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $12.8B | +3.7% | $0.45 | $0.38–$0.61 | — | 4 |
| 2027 | $14.0B | +9.0% | $0.50 | $0.41–$0.66 | — | 4 |
| 2028 | $15.7B | +12.8% | $0.58 | $0.49–$0.61 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 0512.HKGrand Pharmaceutical Group Limited | $4.91 | +0.51% | $17.2B | — |
| 0867.HKChina Medical System Holdings Limited | $10.90 | -2.07% | $26.5B | — |
| 1066.HKShandong Weigao Group Medical Polymer Company Limited | $3.17 | +0.00% | $14.1B | — |
| 1513.HKLivzon Pharmaceutical Group Inc. | $20.80 | -1.33% | $22.7B | — |
| 1833.HKPing An Healthcare and Technology Company Limited |
| $5.99 |
| -2.76% |
| $12.7B |
| — |
| 2096.HKSimcere Pharmaceutical Group Limited | $11.25 | -1.23% | $28.9B | — |
| 2575.HKXuanzhubio-b | $8.30 | -2.12% | $4.3B | — |
Source: Financial Modeling Prep · peers by sector/industry